Skip Navigation
Skip to contents

JPTM : Journal of Pathology and Translational Medicine


Author index

Page Path
HOME > Articles and issues > Author index
Sun-Hee Heo 1 Article
Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
Miseon Lee, In Ah Park, Sun-Hee Heo, Young-Ae Kim, Gyungyub Gong, Hee Jin Lee
J Pathol Transl Med. 2019;53(3):180-187.   Published online March 11, 2019
  • 5,637 View
  • 184 Download
  • 13 Citations
AbstractAbstract PDF
Most triple-negative breast cancers (TNBCs) have a high histologic grade, are associated with high endoplasmic stress, and possess a high frequency of TP53 mutations. TP53 missense mutations lead to the production of mutant p53 protein and usually show high levels of p53 protein expression. Tumor-infiltrating lymphocytes (TILs) accumulate as part of the anti-tumor immune response and have a strong prognostic and predictive significance in TNBC. We aimed to elucidate the association between p53 expression and the amount of TILs in TNBC.
In 678 TNBC patients, we evaluated TIL levels and expression of endoplasmic stress molecules. Immunohistochemical examination of p53 protein expression was categorized into three groups: no, low, and high expression.
No, low, and high p53 expression was identified in 44.1% (n = 299), 20.1% (n = 136), and 35.8% (n = 243) of patients, respectively. Patients with high p53 expression showed high histologic grade (p < .001), high TIL levels (p = .009), and high expression of endoplasmic reticulum stress-associated molecules (p-eIF2a, p = .013; XBP1, p = .007), compared to patients with low p53 expression. There was no significant difference in disease-free (p = .406) or overall survival rates (p = .444) among the three p53 expression groups.
High p53 expression is associated with increased expression of endoplasmic reticulum stress molecules and TIL influx.


Citations to this article as recorded by  
  • Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
    Sotiris Loizides, Anastasia Constantinidou
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Dihydroartemisinin-Transferrin Adducts Enhance TRAIL-Induced Apoptosis in Triple-Negative Breast Cancer in a P53-Independent and ROS-Dependent Manner
    Xinyu Zhou, Abel Soto-Gamez, Fleur Nijdam, Rita Setroikromo, Wim J. Quax
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • New Challenges in the Differential Diagnosis of High-Grade Triple-Negative Breast Cancer and Serous Carcinoma
    Andrii Puzyrenko, Chandler S Cortina, Julie M Jorns
    International Journal of Surgical Pathology.2022; 30(7): 728.     CrossRef
  • Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer
    Shengnan Sha, Luyi Si, Xinrui Wu, Yuanbiao Chen, Hui Xiong, Ying Xu, Wangrui Liu, Haijun Mei, Tao Wang, Mei Li
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer
    Ai-Yan Xing, Long Liu, Ke Liang, Bin Wang
    Cancer Investigation.2022; 40(10): 879.     CrossRef
  • Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
    Arpita Poddar, Sushma R. Rao, Prashanth Prithviraj, George Kannourakis, Aparna Jayachandran
    Current Oncology.2022; 29(10): 6847.     CrossRef
  • The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting
    Natsuki Furukawa, Vered Stearns, Cesar A. Santa-Maria, Aleksander S. Popel
    Expert Opinion on Therapeutic Targets.2022; 26(12): 1041.     CrossRef
  • Intracellular partners of fibroblast growth factors 1 and 2 - implications for functions
    Katarzyna Dominika Sluzalska, Jakub Slawski, Martyna Sochacka, Agata Lampart, Jacek Otlewski, Malgorzata Zakrzewska
    Cytokine & Growth Factor Reviews.2021; 57: 93.     CrossRef
  • Targeted Chinese Medicine Delivery by A New Family of Biodegradable Pseudo-Protein Nanoparticles for Treating Triple-Negative Breast Cancer: In Vitro and In Vivo Study
    Hiu Yee Kwan, Qinghua Xu, Ruihong Gong, Zhaoxiang Bian, Chih-Chang Chu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells
    Marie Colombe Agahozo, Marcel Smid, Ronald van Marion, Dora Hammerl, Thierry P. P. van den Bosch, Mieke A. M. Timmermans, Chayenne J. Heijerman, Pieter J. Westenend, Reno Debets, John W. M. Martens, Carolien H. M. van Deurzen
    Biology.2021; 10(8): 768.     CrossRef
  • With Our Powers Combined
    Lawrence Kasherman, Katherine Karakasis, Amit M. Oza
    The Cancer Journal.2021; 27(6): 511.     CrossRef
  • The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer

    Li Chen, Xiangyi Kong, Chengrui Yan, Yi Fang, Jing Wang
    OncoTargets and Therapy.2020; Volume 13: 1397.     CrossRef
  • Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer

    Xenia Elena Bacinschi, Anca Zgura, Inga Safta, Rodica Anghel
    Cancer Management and Research.2020; Volume 12: 11965.     CrossRef

JPTM : Journal of Pathology and Translational Medicine